secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001193125-25-117245
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC
-----------------------------------------------------------------------

- Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.
- CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.
- Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.
- Astellas milestone $5M; cash runway into Q2 2026.
- CX-801 Phase 1a data in melanoma expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/0001193125-25-117245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/d23036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-117245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer